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Abstract: Equine influenza is a major respiratory disease of horses that is largely controlled by
vaccination in some equine populations. Virus-neutralising antibodies, the mainstay of the protective
immune response, are problematic in assaying for equine influenza virus, as most strains do not
replicate efficiently in cell culture. Surrogate measures of protective antibody responses include
the haemagglutination inhibition (HI) test and single radial haemolysis (SRH) assay. For this
study, a pseudotyped virus, bearing an envelope containing the haemagglutinin (HA) from the
Florida clade 2 equine influenza virus strain A/equine/Richmond/1/07 (H3N8), was generated
to measure HA-specific neutralising antibodies in serum samples (n = 134) from vaccinated or
experimentally-infected ponies using a pseudotyped virus neutralization test (PVNT). Overall,
the results of PVNT were in good agreement with results from the SRH assay (100% sensitivity,
68.53% specificity) and HI test (99.2% sensitivity, 49.03% specificity). The PVNT was apparently
more sensitive than either the SRH assay or the HI test, which could be advantageous for studying
the antibody kinetics, particularly when antibody levels are low. Nevertheless, further studies
are required to determine whether a protective antibody level can be defined for the SRH assay
and to ascertain the inter-laboratory reproducibility. In conclusion, the PVNT efficiently measures
neutralising antibodies after immunization and/or experimental infection in the natural host, and may
complement existing antibody assays.
Keywords: equine influenza; horse; pseudotype virus; vaccine
1. Introduction
Equine influenza (EI) is a major respiratory disease of horses (Equus ferus caballus) caused by
influenza A virus (IAV), which can result in important welfare issues and significant loss for the equine
industry, as illustrated in Australia in 2007 [1] and more recently in the United Kingdom, when horse
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racing was stopped for six days in early 2019. Vaccination is used globally to prevent equine influenza
virus (EIV) infections [1,2]. Since the first inactivated whole virus vaccines were introduced in the 1960s,
various vaccine types have been developed, with inactivated whole virus, subunit, live-attenuated,
and viral-vector-based vaccines in current use (reviewed by Paillot, 2014 [1]). Protection elicited by IAV
vaccination requires stimulation of a humoral immune response and cell-mediated immunity required
for virus-infected cell clearance. A neutralising antibody (NAb) against the major viral surface protein,
haemagglutinin (HA), is one of the primary vaccine-induced lines of defence, because it prevents
IAV cell binding and entry [3]. In the human field, the contribution to protection of NAb against the
other surface protein, neuraminidase (NA), which interferes with the release of virions [3], has been
increasingly recognized [4]. As for human seasonal influenza vaccines, the strain content of EIV
vaccines is reviewed annually and updated periodically to maintain vaccine effectiveness. In the last
decade, circulating EIV has belonged to one of two clades in the Florida lineage of the H3N8 subtype
(FC1 or FC2). The latest recommendation from the World Organisation for Animal Health (OIE)
Expert Surveillance Panel on EI Vaccine Composition is that equine influenza vaccines should contain
both a clade 1 virus (represented by A/equine/South Africa/04/2003-like or A/equine/Ohio/2003-like
viruses) and a clade 2 virus (represented by A/equine/Richmond/1/2007-like viruses) (https://www.oie.
int/scientific-expertise/specific-information-and-recommendations/equine-influenza/).
Virus-neutralization tests are widely regarded as the gold standard for measuring protective
antibody responses to virus vaccination. However, influenza A viruses typically do not induce
visible cytopathic effects (CPE), which is the usual read-out for cell culture-based virus neutralization
tests. Furthermore, most EIV isolates replicate poorly in cell cultures, and the alternative approach
of performing neutralization tests in embryonated hens’ eggs is extremely cumbersome. For these
reasons, the haemagglutination inhibition (HI) test, which measures inhibition of HA binding to
receptors on red blood cells, has been the mainstay of testing antibody responses to influenza A
viruses [5]. The single radial haemolysis (SRH) assay, which measures complement-mediated lysis of
red blood cells coated with whole virus, was introduced as a more reproducible assay for measuring
influenza antibodies. Measurement of SRH antibody levels provides a well-established correlate of
protection against EIV infection, with defined thresholds associated with virus shedding reduction
and clinical protection [6–8]. More recently, pseudotyped viruses (PVs) based on lentivirus vectors,
have been generated to measure equine influenza neutralising antibodies in horse serum and have
demonstrated reasonable correlation (correlation coefficient r = 0.65) with the SRH assay for detecting
antibody levels [9,10]. PVs are non-replicating, hybrid viruses with the disabled core of a vector
virus and the envelope protein (or proteins) of the study virus (e.g., influenza virus haemagglutinin).
The PVs also incorporate a reporter gene, such as firefly luciferase, flanked by lentivirus long terminal
repeats. This leads to the reporter gene being inserted into the genome of transduced target cells and
subsequently expressed, providing a direct quantitative readout of the amount of virus entering the
cells, which is a major advantage for viruses like EIV that do not cause CPE.
The current study aimed to evaluate a pseudotyped virus neutralization test (PVNT) for
measurement of EIV-specific NAb response in the natural host following vaccination or experimental
infection with EIV, and to compare with responses measured by SRH or HI assays.
2. Materials and Methods
2.1. Serum Samples
Two sets of serum samples obtained from vaccination and experimental infection studies unrelated
to this work were used in this study. The first set contained 108 samples collected from 27 Welsh
mountain ponies (Equus ferus caballus, Welsh section A breed, also called Welsh Mountain Pony
breed, United Kingdom) vaccinated with two doses of vaccine and sampled at four time points
(Table 1). The sampling time points were day 0 (D0: when the first vaccine dose was given), day 28
(D28: when a second vaccine dose, V2, was given), day 56 (D56: 4 weeks after V2), and day 238
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(D238: 30 weeks after V2). Groups 1–4 received two doses of non-commercial, inactivated whole
virus vaccine containing either A/equine/Richmond/1/2007 (FC2) or A/equine/Kentucky/2009 (FC1).
Group 5 received phosphate-buffered saline (PBS) only, and group 6 were vaccinated with ProteqFlu,
a commercial canarypox-vectored vaccine expressing only the HA protein of equine influenza virus
strains A/equine/Ohio/2003 (FC1) and A/equine/Richmond/1/2007 (FC2).
Table 1. Details of serum set #1. HAU/mL = haemagglutinin (HA) unit per mL.
Group n (Ponies) n (Samples) Vaccine
1 5 20 A/equine/Richmond/1/2007 (FC2; 400 HAU/mL)
2 5 20 A/equine/Richmond/1/2007 (FC2; 100 HAU/mL)
3 5 20 A/equine/Kentucky/2009 (FC1; 400 HAU/mL)
4 5 20 A/equine/Kentucky/2009 (FC1; 100 HAU/mL)
5 4 16 None (control group)
6 3 12 Commercial vaccine 1
Total: 27 108
1 ProteqFlu (Merial) contains A/equine/Ohio/2003 (FC1) and A/equine/Richmond/1/2007 (FC2).
The second serum set contained 26 serum samples from Welsh mountain ponies with mixed
EI vaccination history, sampled 14 days after experimental infection with influenza A/equine/
Cambremer/2012 (H3N8 FC2). Ponies had recovered from the infection at the time of sampling.
Both sets of sera were stored at −20◦C prior to use.
2.2. Single Radial Haemolysis (SRH) Assay
Antibodies were measured by single radial haemolysis (SRH) assay [5] against the EIV strain
A/equine/Richmond/1/2007 (H3N8), as previously described [5] (Figure 1A). Control antiserum against
A/equine/South Africa/4/2003 (H3N8; Florida Clade 1; ref EU SA/4/03 Y0000712) from the European
Directorate for the Quality of Medicines and Healthcare (EDQM) was included on each plate [11].
The amount of SRH antibody is expressed as the area of haemolysis (mm2).
2.3. Haemagglutination Inhibition (HI) Test
HI antibody titers were expressed as the last dilution of serum that inhibited chicken red blood
cell haemagglutination by A/equine/Richmond/1/2007 (H3N8), as previously described [5] (Figure 1B).
As mentioned in the OIE Terrestrial Manual, a cut-off point for positive samples has not been determined
for the HI test [5]. In the current study, a titer >1:8 was regarded as positive. For statistical and
graphical reasons, an HI titer <1:8 was converted to 4. Values for in-house reference serum standards
were within the expected range.
2.4. Pseudotyped Virus Neutralization Test (PVNT)
Lentivirus particles pseudotyped with the A/equine/Richmond/1/2007 HA were produced as
described in Scott et al., 2016 [10]. Briefly, four plasmids expressing the EIV HA gene, an HA-cleaving
protease (i.e., TMPRSS2), the HIV gag-pol genes, and a manipulated HIV genome containing the
luc reporter gene replacing endogenous genes, were co-transfected into HEK293/17 (PV producer)
cells (see Figure 1C). Exogenous neuraminidase was added after 24 h to allow viral particle release,
with supernatant harvesting after a further 24 h. PVNTs were conducted as previously described [9]
(Figure 1C). Briefly, PV diluted to produce a signal of 106 relative light units (RLUs) was incubated
with serially two-fold diluted serum samples for 1 h at 37 ◦C before HEK293T/17 cells were added and
plates incubated for 48 h. No serum and cell only controls were also included. Luciferase expression
was quantified using BrightGlo reagent (Promega), and the serum titres obtained expressed as a 50%
inhibitory concentration (logIC50).
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2.5. Statistical Analysis
All statistical analysis was performed using StatGraphics Centurion XVI Version 16.1.12 for
windows (StatPoint Technologies, Inc). Significance levels were set at p < 0.05. The receiver operating
characteristic (ROC) curves were generated and analyzed using the web-based calculator for ROC
curves (Eng J. ROC analysis: web-based calculator for ROC curves; Baltimore: Johns Hopkins
University (updated 19 March 2014), available from http://www.jrocfit.org).
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Figure 1. Serological assay/tests to measure equine influenza virus (EIV)-specific antibody response. 
(A) Single radial haemolysis (SRH) assay: (A.1.) sheep red blood cells (RBCs) are sensitized with EIV, 
(A.2.) EIV-sensitized RBCs are mixed with guinea-pig complement and melted agar, and (A.3) poured 
onto an immunoplate. When the gel is set, 10 µ l of heat-inactivated undiluted serum is placed in the 
punched hole. The plate is incubated for 20 to 24 h at 30 °C to allow serum diffusion prior to 
measurement of the haemolysis area. (B) Haemagglutination inhibition (HI) test: (B.1.) in the absence 
of EIV, chicken RBC sediment to the bottom of round-bottomed wells of a 96-well plate; (B.2.) in the 
presence of EIV and RBC agglutinate; (B.3.) the incubation of EIV with a serum containing EIV-
specific antibody prevents the RBC agglutination; (B.4) an example of a serum titration (i.e., HI titer 
of 1:8). (C) Pseudotyped virus neutralisation test (PVNT), adapted from ref [9]: (C.1.) to generate 
lentivirus pseudotypes, four plasmids expressing EIV HA, HIV gag-pol, firefly luciferase reporter 
gene, and an HA-cleaving protease (e.g. TMPRSS2) are transfected into a packaging cell. EIV HA 
pseudotyped particles are released in the supernatant, harvested, then titrated on an influenza-
permissive cell line. (C.2.) The level of reporter gene expression is measured in this target cell culture. 
(C.3.) The pre-incubation of influenza HA-pseudotyped virus with a serum containing EIV-specific 
antibody reduces cell infection and the associated reporter gene expression. 
3. Results 
3.1. Defining PVNT Threshold for Positivity 
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antibody prevents the RBC agglutination; (B.4) an example of a serum titration (i.e., HI titer of 1:8).
(C) Pseudotyped virus neutralisation test (PVNT), adapted from ref [9]: (C.1.) to generate lentivirus
pseudotypes, four plasmids expressing EIV HA, HIV gag-pol, firefly luciferase reporter gene, and an
HA-cleaving protease (e.g., TMPRSS2) are transfected into a packaging cell. EIV HA pseudotyped
particles are released in the supernatant, harvested, then titrated on an influenza-permissive cell line. (C.2.)
The level of reporter gene expression is measured in this target cell culture. (C.3.) The pre-incubation of
influenza HA-pseudotyped virus with a serum containing EIV-specific antibody reduces cell infection
and the associated reporter gene expression.
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3. Results
3.1. Defining PVNT Threshold for Positivity
All 27 D0 samples in serum set #1 tested negative for EIV antibodies in the SRH assay (<3 mm2)
and HI test (<1:8). The mean logIC50 for these samples was 0.2± 0.4, with all samples below 1.9 logIC50,
which was previously considered as the positivity threshold [9]. As expected, unvaccinated control
ponies (group 5) remained seronegative by SRH assay and HI test at all time points (Figure 2). While the
logIC50 remained low for these animals, the mean logIC50 was 0.7 ± 1.0 for samples from D0 to D238
(n = 16), and four serum samples reached 1.9 logIC50. The distribution of logIC50 results obtained
for these seronegative serum samples when measured by SRH or HI (n = 39) indicates that the 95%
upper limit in the PVNT is a neutralising antibody titer of 2.21 logIC50, which was therefore used as
the threshold for positivity in this report.
3.2. Post-Vaccination Antibody Responses
Sera from all ponies in groups 1 and 3 of serum set #1, which received the higher dose of the
monovalent vaccines, had antibody levels above the threshold in the PVNT at 4 weeks after the first
dose of vaccine (D28). All horses in group 1, and four of the five horses in group 3, were positive in the
SRH assay at D28, whereas only two ponies in group 1 and one pony in group 3 had positive HI titers
(1:8) at D28 (Figure 2).
In all of the groups of ponies that received a vaccine, the peak titer measured in the PVNT occurred
on D56 (4 weeks after the second vaccine dose), except for one pony in group 2, which received the low
dose of the FC2 vaccine and had the highest logIC50 on D28 (indicating a good response to priming
immunization). The PVNT response at D56 was lower for this specific pony, which tends to indicate
that the peak occurred earlier after V2 and that the response had started to decline when measured
at this time point. This pony was the only member of group 2 to have a measurable SRH antibody
response on D28, with high SRH and HI antibody titers at D56 when compared with the ponies from
the same group, which also indicates a good response to both priming and boost immunization (V1 and
V2, respectively). The peak HI antibody titres all occurred at D56.
Although the PVNT titres declined between D56 and D238 in the majority of vaccinated ponies,
most remained above the positive threshold value of 2.21 logIC50. The SRH values also declined
between D56 and D238, with only nine ponies remaining seropositive at D238 (three, four, and two
ponies in groups 1, 3, and 6, respectively). In terms of the HI antibody response, five ponies in groups
1 to 4 remained seronegative at all time points, and only one pony (in group 1) had a measurable HI
titre of 1:8 on D238.
Multifactorial analyses indicated that the vaccine dose had a significant effect on the logIC50
measured by PVNT from D28 to D238 (D0 excluded, p = 0.0106 with time point and EIV strain effects
removed). The EIV vaccine strain had no significant effect on logIC50 when measured from D28 to 238
(D0 excluded, p = 0.300 with time point and dose effects removed). Multifactorial analysis of SRH
antibody values gave similar results to those obtained for the PVNT antibody response; the vaccine
dose had a significant effect on the SRH value when measured from D28 to D238 (D0 excluded,
p = 0.0063 with time point and EIV strain effects removed). As for the PVNT antibody response,
the EIV strain had no significant effect on the SRH antibody value when measured from D28 to 238
(D0 excluded, p = 0.88 with time point and dose effects removed). These results indicate that both
PVNT and SRH tests were responsive to the dose of vaccine administered, with no measurable effect
of the EIV strain incorporated in the vaccine used. The low level of HI-positive serums at D28 and
D238, combined with a large response heterogeneity at D56 (e.g., from 4 to 64 in groups 1, 3, and 4) did
not allow any meaningful statistical analysis.
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Figure 2. Serum set #1 antibody response kinetics per group, measured by (A) pseudotype virus
neutralization test (PVNT), (B) single radial haemolysis (SRH), and (C) hemaglutination inhibition
(HI) assays. The dotted line represents the calculated positive threshold (2.21 logIC50) for the
PVNT. The number of ponies per group is indicated (n). D values indicate days after immunization.
HAU/mL = HA unit per mL. Groups 1 and 2 are indicated in blue, groups 3 and 4 are indicated in red,
and the control group 5 and HA vaccine group 6 are indicated in white and green, respectively.
Vaccines 2020, 8, 466 7 of 11
3.3. Comparison of PVNT with SRH and HI
For comparison of the results obtained by PVNT with those obtained by SRH and HI, results from
both serum sets were used (134 serum samples). The 26 serum samples from serum set #2
(collected 2 weeks after experimental infection with EIV) were all positive by PVNT, with logIC50
values ranging from 3.94 to 11.61. They were also all positive by SRH (98.6 to 204.1 mm2) and HI (1:8 to
1:1028) (Table S1). These results confirmed the seroconvertion induced by the experimental infection
with the EIV strain A/equine/Cambremer/2012.
The direct correlation analysis between the SRH and PVNT results provided a correlation coefficient
r and a determination coefficient R2 of 0.84 and of 0.70, respectively (n = 134) (Figure 3A). The direct
correlation analysis between the HI and VN antibody titres provides a correlation coefficient r and
R2 values of 0.77 and 0.59, respectively (n = 134) (Figure 3C). As observed with the SRH comparison,
PVNT performed well at time points where the HI antibody response was of low amplitude (D28 and
D238 in all EI vaccine groups). At time points where HI antibody titres were measurable, PVNT results
correlated well with the HI antibody titres.
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Figure 3. Pseudotype virus neutralization (VN)/single radial haemolysis (SRH) and VN/hemaglutination
Inhibition (HI) assay ((A,C), respectively), as well as receiver operating characteristic (ROC) curve analysis
((B,D), respectively). Results from both serum sets were used (n = 134). TPF: true positive fraction.
Vaccines 2020, 8, 466 8 of 11
Results from both sets of samples were also used to compare the PVNT with the SRH assay
(considered as gold standard for the analysis) by ROC curve analysis (Figure 3B). The calculated area
under the curve (AUC) was high at 0.9906 (99.06 ± 0.008%), which indicated a very good performance
of the PVNT. According to this analysis, the positive threshold value of 2.21 logIC50, defined in
Section 3.1, gave 100% sensitivity and 68.53% specificity (sensitivity is the proportion of true-positives
that actually test positive, and how well a test is able to detect positive individuals in a population;
specificity is the proportion of true-negatives that actually test negative, and reflects how well an assay
performs in a group of disease negative individuals). The specificity value could be explained by
the higher sensitivity of the PVNT, with 19 serum samples ≥2.21 logIC50 but negative by SRH assay.
A PVNT threshold value of 3.14 logIC50 was associated with 97.47% sensitivity and 95.05% specificity.
The ROC curve analysis for the PVNT against the HI test (considered as gold standard for this analysis)
calculates an AUC of 0.9584 (95.84 ± 0.016%) that also confirms a good performance of the PVNT
(Figure 3D). The positive threshold value of 2.21 logIC50 defined in Section 3.1 gave 99.2% sensitivity
and 49.03% specificity, which could be explained by the higher sensitivity of the PVNT, with 43 serum
samples ≥2.21 logIC50 but negative by HI test. A PVNT threshold value of 3.14 logIC50 is associated
with 97.47% sensitivity and 95.05% specificity. Above a PVNT threshold of 3.4 logIC50, the sensitivity
decreases to below 95%, while the specificity is 79.34%.
4. Discussion
Pseudotyped viruses presenting the surface proteins of numerous viruses have been exploited
for different applications: from basic cell tropism and receptor studies [12,13], through to antiviral
screening, serological surveillance [14,15] vaccine efficacy evaluation, and even as vaccine antigens
themselves [16–18]. A major use of PVs is in the sensitive measurement of neutralising antibody
responses in sera following natural infection or vaccination. In a previous pilot study, the PVNT
demonstrated reasonable correlation (r = 0.65) with SRH for detecting antibody levels in equids [9].
In the current study, the PVNT was applied to a larger sample set, and antibody detection compared
with both SRH and HI.
4.1. Defining PVNT Threshold for Positivity
In the pilot study from Scott et al. [10], a threshold of 1.9 logIC50 was considered as the
positivity threshold for the PVNT, using a PV displaying the HA of A/equine/Sussex/1989 (H3N8) [9].
This was redefined in the current study using pre-vaccination serum samples and serum samples
from unvaccinated ponies as 2.21 logIC50. Although this value was associated with 100% specificity
(using SRH as the gold standard), specificity was only 68.53% on ROC analysis. Defining a threshold
value of 3.14 logIC50 gave 95% specificity and 97.5% sensitivity. This suggests that the positive
threshold value should be carefully evaluated before applying the PVNT to study antibody responses.
Further studies are also required to determine whether clinical and/or virological antibody thresholds
can be assigned to the PVNT (thresholds above which clinical signs of disease and virus shedding are
significantly reduced, respectively).
4.2. Post-Vaccination Antibody Responses
As previously observed [9], using the PVNT provides measurable titers at time points when the
SRH antibody response is of low amplitude (example of SRH antibody kinetics described in [19–21]),
such as on D28 in both low-dose vaccine groups (groups 2 and 4) and at D238 in all vaccinated groups.
The ability of PVNT to measure a neutralising antibody titre when both SRH assay and HI test reached
their limit of detection will be useful to define antibody response and kinetics at the early stages
of immunization (i.e., in the days and weeks after V1), as well as the decrease of maternal-derived
antibodies (MDAs) acquired by foals through colostrum consumption (when the mare is EI-vaccinated
in the last week of gestation). Such data may be useful to avoid EI vaccination in the presence of MDA,
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which is recommended for most EI vaccines and has been shown to decrease the immunogenicity of
some [1,19,22–24].
The availability of serum samples collected seven months after a second dose of vaccine (D238 of
the study) allowed the performance of the PVNT during the “immunity gap” to be tested. This is the
well-characterized period of susceptibility to EI infection between the second and third immunizations
of a standard vaccination protocol when EIV-specific SRH antibody titers decrease sharply below the
clinical protection threshold [6,7]. At this time point, the PVNT appears to be more sensitive than the
SRH assay and the HI test. Alternatively, the neutralising antibody response may last longer when
compared with the SRH and HI antibody responses.
At time points where SRH antibodies were measurable, PVNT provided a more homogeneous
measurement of the antibody response at the group level. Under the conditions of this study, PVNT
appeared to be less advantageous when used at the peak of immunity or for correlation with clinical or
virological protection, as it could be less discriminatory than the SRH assay. However, further analyses
are warranted.
4.3. Comparison of PVNT with SRH and HI
The SRH assay has previously been demonstrated to be more reproducible than the HI test when
a reference serum is used [11,25]. Several inter-laboratory studies have shown that the HI test lacks
reproducibility and consistency because it uses reagents that are difficult to standardize (such as red
blood cells). On the other hand, the SRH assay can be adjusted (e.g., by titrating the amount of virus
to use in the assay or the incubation period) in order to ensure that a reference serum falls into the
expected range [11,25]. The reproducibility of the PVNT has yet to be addressed in the same way.
Results obtained in this study demonstrate that the PVNT allowed the sensitive measurement of
neutralising antibodies in all immunized ponies at all time points after immunization. The correlation
coefficient (R2) between the PVNT and SRH values was 0.70 (p < 0.0001), which is higher than with HI
(0.59) and similar to the correlation found in the pilot study using the A/equine/Sussex/1989 strain [9].
This correlation is lower than previously reported for a virus neutralization test using an ELISA to detect
the production of virus proteins and SRH for antibodies specific for two strains of the H3N8 subtype
of equine influenza virus (Spearman rank correlation coefficients of 0.882 and 0.901) [26]. This result
could be linked to differences in the serum set composition between the two studies, with half of the
serums taken three weeks after EIV field infection. Post-infection serum samples represented less
than 20% of the serum collection used in the current study. However, correlation coefficients can
vary between strains. Trombetta et al. demonstrated correlation coefficients of between 0.69 and 0.86
(Pearson’s R) between a microneutralization test and SRH for human influenza viruses [27].
Overall, the PVNT efficiently measures neutralising antibodies, which will greatly supplement
results obtained with the HI test and SRH assay (HA binding inhibition and complement-binding
antibody responses, respectively). However, a guideline on the utility and use of results obtained
from different serological assays in the context of vaccine trials or sero-epidemiological studies may be
required, and standardization methods would need to take into account the test/assay purpose.
4.4. Comparison of Heterologous Strains in PVNT and SRH Assays
The PV used in this study presented the HA only of the A/equine/Richmond/1/2007 strain. In this
respect, it is similar to the HI test in only measuring antibodies specific for the HA protein. This would
be appropriate for measurement of antibodies to the ProteqFlu vaccine used in group 6, as this expresses
only the HA protein of EIV in a canarypox virus background. The SRH assay measures antibodies
against the NA also, which will contribute to the reduction of viral load during infection. However,
PVs displaying both the HA and NA proteins of EIV have been successfully generated [10].
Vaccination with the heterologous strain (A/equine/Kentucky/2009) used in groups 3 and 4 did
not appear to have a significant effect on the measurement of antibodies in the PVNT. It is believed
that cross-reactive epitopes in the stalk of the HA may be exposed in PVs because the HA protein is
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less densely packed on the surface of PVs than in the native virus [28]. In contrast, because the HI test
measures antibodies that block the receptor binding site, it is more strain-specific. There was also no
significant effect of vaccine strain on SRH antibody levels, which could be explained by that fact that
the SRH assay measures a different type of antibody (complement-mediated lysis), and not just those
against HA.
5. Conclusions
Overall, PVNT antibody responses were in good agreement with SRH/HI antibody responses.
Antibodies are measurable by PVNT at time points when the SRH or HI antibody response is of low
amplitude, which could greatly improve our understanding of the kinetics of the antibody response
to equine influenza vaccination and infection. Further analyses will be required to determine if this
observation is linked to technical (e.g., sensitivity) or biological (e.g., antibody response kinetics)
reasons. In conclusion, the PVNT efficiently measures neutralising antibodies after immunization or
experimental infection in the natural host, which will greatly supplement HA binding inhibition (HI)
and complement-binding antibody (SRH) responses.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-393X/8/3/466/s1,
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